# Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

> **NCT00248040** · PHASE2 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 80 (actual)

## Conditions studied

- Ischemia-Reperfusion Injury
- Kidney Diseases

## Interventions

- **DRUG:** Reparixin continuous infusion
- **DRUG:** reparixin intermittent infusion
- **OTHER:** placebo infusion

## Key facts

- **NCT ID:** NCT00248040
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-05
- **Final completion:** 2008-06
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00248040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00248040, "Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00248040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*